Analyst Scoreboard: 6 Ratings For Xencor
Portfolio Pulse from Benzinga Insights
Analysts have updated their ratings on Xencor (NASDAQ:XNCR), with 6 recent ratings ranging from bullish to indifferent. The average 12-month price target is now $35.33, down from $45.20, reflecting a 21.84% decline. Analyst actions include lowering price targets and maintaining ratings, indicating a cautious but not entirely bearish outlook on the company. Xencor, a clinical-stage biopharmaceutical company, has shown significant revenue growth and strong financial performance indicators such as net margin and ROE.
April 16, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed views on Xencor, with a new average price target of $35.33, reflecting a cautious outlook despite the company's strong revenue growth and financial performance.
The mixed analyst ratings and lowered price targets suggest a cautious outlook for Xencor in the short term. However, the company's significant revenue growth and strong financial indicators such as net margin and ROE could provide a buffer against negative sentiment, leading to a neutral impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100